# US 2011/0135685 A1 · Edible Vaccines Expressed in Soybeans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0135685 A1
- Document ID: US20110135685A1
- Status: Published application
- Kind: A1
- Application number: 12/692,722
- Filed: 2010-01-25
- Published: 2011-06-09
- Earliest claimed: 2004-10-12
- Assignees: SoyMeds, Inc.
- Inventors: Kenneth John Piller; Kenneth Lee Bost
- Web page: https://patentgrep.com/patent/US20110135685A1

## CPC

- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/02: Bacterial antigens
- A61K 39/0258: {Escherichia}
- A61K 39/35: Allergens
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61K 2039/517: {Plant cells}
- A61K 2039/55544: {Bacterial toxins}
- C12N 2710/00088: for redistribution
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylactically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.

## Claims

### Claim 1

An immunogen comprising a transgenic soybean and an adjuvant, wherein the transgenic soybean is transformed with an exogenous nucleotide sequence that expresses an immunogenic protein, wherein the immunogenic protein produces an immunogenic response upon oral administration to an individual,
wherein the exogenous nucleotide sequence expresses one or more immunogenic proteins selected from the group consisting of Escherichia coli fanC, Escherichia coli heat labile toxin subunit A or B (LT-A or LT-B), Bacillus anthracis A (PA toxin), Bacillus anthracis LF toxin, Bacillus anthracis EF toxin, Clostridium tetani exotoxin tetanolysin, Clostridium tetani exotoxin tetanospasmin, any of Clostridium botulinum toxins A-G, human immunodeficiency virus (HIV) protein gp120, HIV protein gp41, HIV protein Gag, HIV protein RT, severe acute respiratory syndrome (SARS) coronavirus Spike glycoprotein, SARS coronavirus nucleocapsid, Herpes simplex virus-2 (HSV-2) gB membrane protein, HSV-2 membrane gD protein, any of vaccinia (smallpox) core proteins, any of smallpox membrane proteins, any of encephalitis virus non-structural (NS) proteins 1-4, and encephalitis virus surface proteins; and
wherein the adjuvant comprises mutant Escherichia heat labile toxin (mLT) or mutant cholera toxin (mCT).

### Claim 2 (depends on 1)

The immunogen according to claim 1, wherein the immunogen produces a protective immune response upon oral administration to the individual.

### Claim 3 (depends on 2)

The immunogen according to claim 2, wherein the protective immune response is against one or more microbial diseases.

### Claim 4 (depends on 2)

The immunogen according to claim 2, wherein the protective immune response comprises at least one of: A) memory T helper lymphocyte response; B) memory cytotoxic T lymphocyte response; and C) memory B lymphocyte response.

### Claim 5 (depends on 1)

The immunogen according to claim 1, wherein the immunogenic protein comprises Escherichia coli fanC or Escherichia coli heat labile toxin subunit B (LT-B).

### Claim 6 (depends on 1)

The immunogen according to claim 1, wherein administration of the immunogen to the individual comprises administration of the adjuvant in conjunction or contemporaneously with the transgenic soybean.

### Claim 7 (depends on 1)

The immunogen according to claim 1, wherein the transgenic soybean comprises the adjuvant, wherein the transgenic soybean is also transformed with a second exogenous nucleotide sequence that expresses the adjuvant in addition to the exogenous nucleotide sequence that expresses the immunogenic protein such that the transgenic soybean co-expresses the immunogenic protein and the adjuvant.

### Claim 8 (depends on 1)

The immunogen according to claim 1, wherein the adjuvant comprises a second transgenic soybean, wherein the second transgenic soybean is transformed with a second exogenous nucleotide sequence that expresses the adjuvant.

### Claim 9 (depends on 1)

The immunogen according to claim 1, wherein the adjuvant comprises a fusion protein comprising a protein sequence that facilitates binding of the adjuvant to epithelial cells in the gastrointestinal tract.

### Claim 10 (depends on 1)

The immunogen according to claim 1, wherein the exogenous nucleotide sequence that expresses the immunogenic protein is operationally linked to a seed-specific promoter.

### Claim 11 (depends on 8)

The immunogen according to claim 8, wherein the second exogenous nucleotide sequence that expresses the adjuvant is operationally linked to a seed-specific promoter.

### Claim 12 (depends on 9)

The immunogen according to claim 9, wherein the second exogenous nucleotide sequence that expresses the adjuvant is operationally linked to a seed-specific promoter.

### Claim 13 (depends on 1)

The immunogen according to claim 1, wherein the transgenic soybean is processed into a transgenic soy product, wherein the transgenic soy product comprises a form selected from the group consisting of soybean seed, soy milk, soy powder, soy flour, and soy flakes, wherein the transgenic soy product is derived from processing of the transgenic soybean.

### Claim 14 (depends on 1)

The immunogen according to claim 1, wherein at least 1% of total protein of the transgenic soybean comprises the immunogenic protein.

### Claim 15 (depends on 1)

A method of treating an individual with the immunogen of claim 1, wherein the immunogen produces a protective immunogenic response upon oral administration to the individual.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the immunogen is administered as a transgenic soy product produced from the transgenic soybean, wherein the transgenic soy product is selected from the group consisting of soybean seed, soy milk, soy powder, soy flour, and soy flakes.

### Claim 17 (depends on 1)

A method of producing the immunogen of claim 1 comprising transforming a soybean plant with the exogenous nucleotide sequence that expresses the immunogenic protein to produce the transgenic soybean, and providing the adjuvant, wherein the transgenic soybean is optionally processed into a transgenic soy product.

### Claim 18 (depends on 17)

The method according to claim 17, wherein administration of the immunogen to the individual comprises administration of the adjuvant in conjunction with or contemporaneously with the transgenic soybean or transgenic soy product.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the transgenic soybean comprises the adjuvant, wherein the soybean plant is transformed with a second exogenous nucleotide sequence that expresses the adjuvant in addition to the exogenous nucleotide sequence that expresses the immunogenic protein such that the transgenic soybean co-expresses the immunogenic protein and the adjuvant.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the adjuvant comprises a second transgenic soybean, wherein a second soybean plant is transformed with a second exogenous nucleotide sequence that expresses the adjuvant to produce the second transgenic soybean.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the transgenic soybean is processed into a transgenic soy product in a form selected from the group consisting of soybean seed, soy milk, soy powder, soy flour, and soy flakes.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the immunogenic protein comprises Escherichia fanC or Escherichia heat labile toxin subunit B (LT-B).

### Claim 23

A bacterial toxin-based mucosal adjuvant comprising a transgenic soybean, wherein the transgenic soybean is transformed with an exogenous nucleotide sequence that expresses a protein that stimulates one or more of the following responses: A) memory T helper lymphocyte response; B) memory cytotoxic T lymphocyte response; or C) memory B lymphocyte response, when the adjuvant is administered to an individual.

### Claim 24 (depends on 23)

The bacterial toxin-based mucosal adjuvant according to claim 23, wherein the adjuvant is administered to the individual contemporaneously or in conjunction with an immunogenic protein.

### Claim 25 (depends on 23)

The bacterial toxin-based mucosal adjuvant according to claim 23, wherein the adjuvant comprises mutant Escherichia heat labile toxin (mLT) or mutant cholera toxin (mCT).
